Risk factors associated with portal vein thrombosis in liver cirrhosis: A case-control study


Cite item

Abstract

Abstract

Background. Portal vein thrombosis (PVT) in patients with liver cirrhosis is a common complication associated with adverse outcomes. The aim of the study was to build a predictive model for PVT in cirrhotic patients.

Materials and methods. A single centre case-control study was carried out. From the database of 1512 cirrhotic patients 94 with newly diagnosed PVT based on contrast-enhanced computed tomography were referred to the Case group. Malignant PVT was an exclusion criterion. Patients without PVT were stratified and matched according to sex, age and etiology of cirrhosis; case-control ratio was 1 : 3-4. The prevalence of PVT in the database, clinical, laboratory, instrumental parameters of the groups were evaluated. Logistic regression model was used to estimate association between variables and PVT.

Results. The overall prevalence of PVT was 6.2% with the highest rates among the patients with HBV infection – 16.7%, nonalcoholic steatohepatitis – 15.6%, alcohol abuse in combination with HCV infection – 11.7%. The best predictive model included variables: Child-Pugh classes B-C (coefficient of regression b=1.853, р=0.001), ascites (b=0.460, р=0.003), hepatocellular carcinoma without vascular invasion (b=2.126, р=0.0001), endoscopic band ligation (b=0.774, р=0.003), transabdominal esophagogastric devascularization procedure (b=2.734, р=0.001), portal hypertensive gastropathy (b=0.793, р=0.017), portal vein diameter (b=0.203, р=0.004), and local factors – ulcerative colitis flare, Clostridium difficile enterocolitis, spontaneous bacterial peritonitis, colorectal cancer, splenectomy, cholecystectomy (b=2.075, р=0.017). The model had accuracy 85.8% (95% CI 81.7-89.4%), sensitivity – 55.1% (95% CI 43.4-66.4%), specificity – 95% (95% CI 91.6-97.3%), and AUC – 0.871 (95% CI 0.826-0.916).

Conclusion. Child-Pugh classes B-C, severe portal hypertension, hepatocellular carcinoma without vascular invasion, and local factors were estimated as risk factors of PVT in cirrhotic patients.

About the authors

M. Yu. Nadinskaia

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: or@hpmp.ru

к.м.н., доц. каф. пропедевтики внутренних болезней

Russian Federation, Moscow

Kh. B. Kodzoeva

Sechenov First Moscow State Medical University (Sechenov University)

Email: or@hpmp.ru

ординатор первого года обучения

Russian Federation, Moscow

K. A. Ulyanova

Sechenov First Moscow State Medical University (Sechenov University)

Email: or@hpmp.ru

ординатор первого года обучения

Moscow

S. I. Rogacheva

Sechenov First Moscow State Medical University (Sechenov University)

Email: or@hpmp.ru

ординатор первого года обучения

Russian Federation, Moscow

A. S. Volkova

Sechenov First Moscow State Medical University (Sechenov University)

Email: or@hpmp.ru

ординатор первого года обучения

Russian Federation, Moscow

A. S. Dekhanov

Sechenov First Moscow State Medical University (Sechenov University)

Email: or@hpmp.ru

ординатор второго года обучения

Moscow

D. A. Strelkova

Sechenov First Moscow State Medical University (Sechenov University)

Email: or@hpmp.ru

студентка шестого курса

Russian Federation, Moscow

V. T. Ivashkin

Sechenov First Moscow State Medical University (Sechenov University)

Email: or@hpmp.ru

д.м.н., проф., академик РАН, зав. каф. пропедевтики внутренних болезней, директор клиники пропедевтики внутренних болезней, гастроэнтерологии и гепатологии им. В.Х. Василенко

Russian Federation, Moscow

References

  1. Botkin S.P. Krankheitsgeschichte eines Falles von Pfortaderthrombose. Archiv f. pathol. Anat. 1864;30(3):449-57. doi: 10.1007/BF02280955
  2. Balfour G.W, Stewart G. Case of enlarged spleen complicated with ascites, both depending upon varicose dilatation and thrombosis of the portal vein. J Med Edinburgh. 1869;14(7):589-99. PMID: 29639641.
  3. Rajani R, Björnsson E, Bergquist A, et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther. 2010;32(9):1154-62. doi: 10.1111/j.1365-2036.2010.04454.x
  4. Sarin S.K, Philips C.A, Kamath P.S, et al. Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis. Gastroenterology. 2016;151(4):574-77.e3. doi: 10.1053/j.gastro.2016.08.033
  5. Tripodi A. Hemostasis in acute and chronic liver disease. Semin Liver Dis. 2017;37(1):28-32. doi: 10.1055/s-0036-1597770
  6. Cool J, Rosenblatt R, Kumar S, et al. Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort. J Gastroenterol Hepatol. 2018;11(10). doi: 10.1111/jgh.14501 [Epub ahead of print].
  7. Amitrano L, Guardascione M.A, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40(5):736-41. doi: 10.1016/j.jhep.2004.01.001
  8. Ghabril M, Agarwal S, Lacerda M, et al. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation. Transplantation. 2016;100(1):126-33. doi: 10.1097/TP.0000000000000785
  9. De Franchis R, Abraldes J.G, Bajaj J, et al. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743-52. doi: 10.1016/j.jhep.2015.07.001
  10. Stine J.G, Wang J, Shah P.M, et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: a matched case - control study. Liver Int. 2018;38(1):94-101. doi: 10.1111/liv.13500
  11. Lankarani K.B, Homayon K, Motevalli D, et al. Risk factors for portal vein thrombosis in patients with cirrhosis awaiting liver transplantation in Shiraz, Iran. Hepat Mon. 2015;15(12):2-5. doi: 10.5812/hepatmon.26407
  12. Mangia A, Villani M.R, Cappucci G, et al. Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol. 2005;17(7):745-51. PMID: 15947552.
  13. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64(1):179-202. doi: 10.1016/j.jhep.2015.07.040
  14. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):71-102.
  15. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-60. doi: 10.1016/j.jhep.2018.03.024
  16. Российское общество хирургов. [Электронный ресурс]. Клинические рекомендации по лечению кровотечений из варикозно расширенных вен пищевода и желудка. 2014. С.9. Режим доступа: http://общество-хирургов.рф/upload/gkk_iz_vven.doc, свободный. Дата обращения 30.08.2018
  17. Леонов В.П. Логистическая регрессия в медицине и биологии [Электронный ресурс]. Режим доступа: http://www.biometrica.tomsk.ru/logit_1.htm - http://www.biometrica.tomsk.ru/logit_8.htm, свободный. Дата обращения: 25.02.2018
  18. Stine J.G, Shah N.L, Argo C.K, et al. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transplant. 2015;21(8):1016-21. doi: 10.1002/lt.24134
  19. Nonami T, Yokoyama I, Iwatsuki S, Starzl T.E. The incidence of portal vein thrombosis at liver transplantation. Hepatology. 1992;16(5):1195-8. doi: 10.1016/0270-9139(92)90014-Z
  20. Merchante N, Rivero-Juárez A, Téllez F, et al. Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis. AIDS. 2017;31(4):493-500. doi: 10.1097/QAD.0000000000001358
  21. Huang L, Yu Q, Wang J. Association between changes in splanchnic hemodynamics and risk factors of portal venous system thrombosis after splenectomy with periesophagogastric devascularization. Med Sci Monit. 2018;24:4355-62. doi: 10.12659/MSM.909403
  22. Piscaglia F, Gianstefani A, Ravaioli M, et al. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transplant. 2010;16(5):658-67. doi: 10.1002/lt.22044
  23. Arab J.P, Martin-Mateos R.M, Shah V.H. Gut - liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int. 2018;12(S1):24-33. doi: 10.1007/s12072-017-9798-x
  24. Carnevale R, Raparelli V, Nocella C, et al. Gut - derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. J Hepatol. 2017;67(5):950-6. doi: 10.1016/j.jhep.2017.07.002
  25. Azzawi Y.A.l, Abboodi Y.A.l, Fasullo M, Kheder J. Risk factors stratifications for portal venous thrombosis (PVT). J Liver. 2017;6(2):2-4. doi: 10.4172/2167-0889.1000208
  26. Kurniawan A, Pratama H.L.N. Clostridium difficile infection is risk factor of portal vein thrombosis in hepatocellular carcinoma patients. Thromb Res. 2018;164:S215. doi: 10.1016/j.thromres.2018.02.076
  27. Moreau N, Wittebole X, Fleury Y, et al. Neutrophil - to - lymphocyte ratio predicts death in acute - on - chronic liver failure patients admitted to the intensive care unit. Shock. 2018;49(4):385-92. doi: 10.1097/SHK.0000000000000993
  28. Sadequl A.S.S.I, Rashid M, Alam M, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatitis B related hepatocellular carcinoma. Gastroenterol Hepatol Int J. 2017;2(2):1-6. doi: 10.23880/GHIJ-16000121
  29. Li Y, Qi X, Li H, et al. D-dimer level for predicting the in - hospital mortality in liver cirrhosis: a retrospective study. Exp Ther Med. 2017;13(1):285-9. doi: 10.3892/etm.2016.3930
  30. Флетчер Р, Флетчер С, Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины. Пер. с англ. 3-е изд. М.: Медиа Сфера; 2004. С. 268.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure 1. Flowchart of the patient enrollment process of study.

Download (21KB)
3. Figure 2. The overall prevalence of portal vein thrombosis and depending on the etiology of cirrhosis.

Download (25KB)
4. Figure 3. The odds ratio and 95% confidence intervals for clinical, laboratory, and imaging features

Download (31KB)
5. Figure 4. ROC curves from the logistic regression models

Download (13KB)

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies